Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Date:8/10/2009

first quarter of 2009 and $0.51 for the second quarter of 2008.

OPERATIONAL HIGHLIGHTS

On May 6, 2009, the FDA granted U.S. marketing approval of Fanapt(TM) for the acute treatment of schizophrenia in adults. Vanda expects to make Fanapt(TM) available in U.S. pharmacies later this year. Holders of a New Drug Application (NDA) have 60 days after approval to file for patent term restoration under the Hatch-Waxman Act. Vanda submitted its application for patent term restoration with respect to Fanapt(TM) on June 9, 2009.

Vanda also continues to pursue its clinical development plan for tasimelteon for the treatment of circadian rhythm sleep disorders. On June 26, 2009, Vanda met with the FDA to discuss the clinical development plan in an End of Phase II Meeting. Vanda will continue to work with the FDA to characterize the path to an NDA for tasimelteon.

FINANCIAL DETAILS

  • Operating Expenses. Second quarter 2009 R&D expenses of $7.2 million consisted primarily of $5.4 million of consulting fees, as well as $0.6 million of salaries and benefits, $0.6 million of non-cash stock based compensation costs for R&D personnel, and $0.3 million of pre-clinical work. This compares to $2.3 million for the first quarter of 2009 and $5.5 million for the second quarter of 2008. The increase in R&D expenses in the second quarter of 2009 relative to the first quarter of 2009 and second quarter of 2008 is primarily due to the $5.0 million in regulatory consulting fees paid and/or accrued as a result of the approval of Fanapt(TM) by the FDA.

  • General and administrative (G&A) expenses of $5.0 million for the second quarter of 2009 consisted primarily of $0.5 million of salaries and benefits and $2.2 million of non-cash stock based compensation costs for G&A personnel, as well as $0.6 mill
    '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Multiporator , , , , , , , , ... Protocol No. 4308 915.029 11/1999 , , , , , ... , Cell line , 293 T, human embryonal kidney, ... Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.541 03/2002 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
... Electroporator 2510 , , , , , , , , ... Protocol No. 4308 915.534 01/2002 , , , , ... , Microorganism , Staphylococcus epidermidis, ... Bacteria, gram positive, , , ...
Cached Biology Technology:293 T 2Streptococcus salivarius 2Staphylococcus epidermidis 2
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
... Reverse Transcriptase (RT) is an improved version ... is a DNA polymerase that synthesizes a ... or an RNA:DNA hybrid. This enzyme is ... mutations rather than a deletion in the ...
... SuperScript™ II RNase H- Reverse Transcriptase (RT) ... RNase H- RT. It is a DNA ... from single-stranded RNA DNA or an RNA:DNA ... the introduction of point mutations rather than ...
... (PNK) catalyzes the transfer of the ... of single- and double-stranded DNA, RNA, ... removes the 3'-phosphate from 3'-phosphoryl polynucleotides, ... to form a 3'-hydroxyl group. Storage ...
Biology Products: